Skip to content
drillr.ai
Sign up

CSTL

CASTLE BIOSCIENCES INC

NASDAQ · Healthcare · Medical - Diagnostics & Research · US

$32.17
+0.64%
Ask drillr

  • Oct 15, 2026, 11:00 UTC

    Castle Biosciences announced that it will release financial results for the third quarter and nine months ended September 30, 2026, after market close on November 5, 2026.

    Source:

  • Oct 12, 2026, 20:30 UTC

    Castle Biosciences announced that data from three studies evaluating its TissueCypher Barrett's Esophagus test will be presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.

    Source:

  • Sep 30, 2026, 20:30 UTC

    Castle Biosciences announced it will present new DecisionDx-Melanoma data at the EADV Congress 2026, supporting its use in sentinel lymph node biopsy decision-making and risk-aligned post-surgical management.

    Source:

  • Sep 28, 2026, 11:00 UTC

    Castle Biosciences announced the publication of a study showing its TissueCypher Barrett's Esophagus Test changed management for 90% of patients with non-dysplastic Barrett's esophagus at an expert surgery center.

    Source:

  • Sep 27, 2026, 03:46 UTC

    Castle Biosciences CEO Derek J. Maetzold sold 14,496 shares of common stock on September 21, 2026, for a total value of $512,201 under a Rule 10b5-1 plan adopted on June 2, 2026.

    Source:

  • Sep 24, 2026, 20:30 UTC

    Castle Biosciences announced the publication of a new study highlighting the clinical need for molecular guidance in atopic dermatitis treatment selection, reinforcing the value of its AdvanceAD-Tx test.

    Source:

  • Sep 22, 2026, 11:00 UTC

    Castle Biosciences announced the opening of a new 55,000-square-foot laboratory and office facility in Scottsdale, Arizona.

    Source:

  • Sep 15, 2026, 11:00 UTC

    Castle Biosciences announced the publication of a decision modeling study showing its TissueCypher Barrett's Esophagus test improves risk-aligned management for patients with Barrett's esophagus.

    Source:

  • Sep 9, 2026, 20:30 UTC

    Castle Biosciences announced the publication of a multi-center study in the Journal of the American Academy of Dermatology validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma.

    Source:

  • Jul 30, 2026, 22:06 UTC

    Castle Biosciences reported second-quarter 2026 revenue of $103.5 million, up 20% year-over-year.

    Source:

  • Jul 14, 2026, 20:30 UTC

    Castle Biosciences received assay approval from the New York State Department of Health for its AdvanceAD-Tx test.

    Source:

  • Jun 16, 2026, 11:00 UTC

    Castle Biosciences' TissueCypher Barrett's Esophagus Test surpassed 100,000 clinical test orders.